Tweet
Profile
Acorda Therapeutics, Inc.
15 Skyline Drive
Hawthorne, NY 10532
United States - Map
Phone: 914-347-4300
Fax: 914-347-4560
Website: http://www.acorda.com
Details
Index Membership: N/A
Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 305
Business Summary
Acorda Therapeutics, Inc., a commercial stage biopharmaceutical company, involves in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury, and other nervous system disorders. Its marketed products include Ampyra (dalfampridine), a potassium channel blocker for improving walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company’s pipeline also includes various products in development for the treatment, regeneration, and repair of the spinal cord and brain. Its early-stage programs include 3 biologic therapeutic approaches for restoring neurologic and cardiac function, which comprise Neuregulin Program for developing GGF2, a molecule in the Phase I clinical trial for the treatment of heart failure; Remyelinating Antibodies Program for developing rHIgM22, an antibody in the preclinical stage for treating MS; and Chondroitinase Program, a research stage program focused on developing chontroitinase as a therapeutic to break down inhibitory factors in the scar tissue that develops as a result of an injury to the CNS. The company also holds license for the development and commercialization of AC105, a proprietary magnesium formulation as an acute treatment SCI and traumatic brain injury. Acorda Therapeutics sells its products through specialty sales force, managed markets team, and contract pharmaceutical telesales organizations primarily in the United States. The company was founded in 1995 and is based in Hawthorne, New York.
Acorda Therapeutics, Inc.
15 Skyline Drive
Hawthorne, NY 10532
United States - Map
Phone: 914-347-4300
Fax: 914-347-4560
Website: http://www.acorda.com
Details
Index Membership: N/A
Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 305
Business Summary
Acorda Therapeutics, Inc., a commercial stage biopharmaceutical company, involves in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury, and other nervous system disorders. Its marketed products include Ampyra (dalfampridine), a potassium channel blocker for improving walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company’s pipeline also includes various products in development for the treatment, regeneration, and repair of the spinal cord and brain. Its early-stage programs include 3 biologic therapeutic approaches for restoring neurologic and cardiac function, which comprise Neuregulin Program for developing GGF2, a molecule in the Phase I clinical trial for the treatment of heart failure; Remyelinating Antibodies Program for developing rHIgM22, an antibody in the preclinical stage for treating MS; and Chondroitinase Program, a research stage program focused on developing chontroitinase as a therapeutic to break down inhibitory factors in the scar tissue that develops as a result of an injury to the CNS. The company also holds license for the development and commercialization of AC105, a proprietary magnesium formulation as an acute treatment SCI and traumatic brain injury. Acorda Therapeutics sells its products through specialty sales force, managed markets team, and contract pharmaceutical telesales organizations primarily in the United States. The company was founded in 1995 and is based in Hawthorne, New York.